EDIT vs MA
Editas Medicine Inc (EDIT) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
EDIT currently screens at market cap $375.2M. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the EDIT and MA stock pages for the full models.
Not investment advice.